Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival

• DOI: 10.1186/s12885-015-1648-4
• Publication Date: 2015-09-22T23:31:21Z
• Authors: Tadeu Ferreira Paiva; Victor Hugo Fonse...; Raul Amorim Marques; Alexandre André B...; Mariana Petaccia ...; Patricia Maria Pe...; Aline Damascena; Benedito Mauro Rossi; Maria Dirlei Begnami; Vladmir Cláudio C...
• Keywords: Surgical oncology

The development of targeted therapies has undoubtedly broadened therapeutic options for patients with colorectal cancer (CRC). use bevacizumab to reduce angiogenesis been associated improved clinical outcomes. However, an urgent need prognostic/predictive biomarkers anti-angiogenic still exists. Clinical data 105 CRC treated in conjunction chemotherapy were analyzed. expression vascular endothelial growth factor (VEGF) receptors, NOTCH1 receptor and its ligand DLL4 determined by immunohistochemistry. Tumor samples arranged on a tissue microarray. association between protein clinicopathological characteristics outcomes was determined. Bevacizumab administered as first-line treatment 70.5 % our cases. median progression-free survival (PFS) 10.2 months. overall (OS) the total cohort 24.4 Bevacizumab, treatment, presence liver metastasis independently objective response rate. Membrane VEGFR1 VEGFR3 expressions lung metastasis; interestingly, less metastasis. lymph node There trend toward PFS lower (p = 0.06). Improved OS significantly 0.01). In multivariate analysis, ECOG (Eastern Cooperative Oncology Group) performance status, metastasis, histological grade, OS. Our findings illustrated profile angiogenesis-related proteins their is detrimental prognostic metastatic plus bevacizumab.